We are the only study that excluded participants according to the complete thyroid status (including all thyroid hormones and thyroid antibodies), a valid history of malignancy, anemia, renal or hepatic dysfunction, sex hormone replacement therapy, use of medications that affect bone metabolism, and those with parathyroid hormone (PTH), calcitonin (CT) and total serum calcium levels outside of the referent ranges. The gene discussed is PLXNA3; the disease is anemia (phenotype).